Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate-specific antigen screening can be beneficial to younger and at-risk men.

Literature DB >> 22566532

Prostate-specific antigen screening can be beneficial to younger and at-risk men.

Monique J Roobol¹, Chris H Bangma, Stacy Loeb.

Abstract

Entities: Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22566532 PMCID： PMC3537779 DOI： 10.1503/cmaj.111962

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

34 in total

1. Comorbidity and mortality results from a randomized prostate cancer screening trial.

Authors: E David Crawford; Robert Grubb; Amanda Black; Gerald L Andriole; Ming-Hui Chen; Grant Izmirlian; Christine D Berg; Anthony V D'Amico
Journal: J Clin Oncol Date: 2010-11-01 Impact factor: 44.544

2. Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions.

Authors: Monique J Roobol; Sigrid Carlsson; Jonas Hugosson
Journal: Evid Based Med Date: 2011-01-12

3. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Authors: Monique J Roobol; Melissa Kerkhof; Fritz H Schröder; Jack Cuzick; Peter Sasieni; Matti Hakama; Ulf Hakan Stenman; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis Denis; Franz Recker; Antonio Berenguer; Mirja Ruutu; Paula Kujala; Chris H Bangma; Gunnar Aus; Teuvo L J Tammela; Arnauld Villers; Xavier Rebillard; Sue M Moss; Harry J de Koning; Jonas Hugosson; Anssi Auvinen
Journal: Eur Urol Date: 2009-07-28 Impact factor: 20.096

4. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.

Authors: A V D'Amico; D Schultz; M Loffredo; R Dugal; M Hurwitz; I Kaplan; C J Beard; A A Renshaw; P W Kantoff
Journal: JAMA Date: 2000-09-13 Impact factor: 56.272

5. Prostate-cancer mortality at 11 years of follow-up.

Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal: N Engl J Med Date: 2012-03-15 Impact factor: 91.245

6. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544

7. PSA screening among elderly men with limited life expectancies.

Authors: Louise C Walter; Daniel Bertenthal; Karla Lindquist; Badrinath R Konety
Journal: JAMA Date: 2006-11-15 Impact factor: 56.272

8. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.

Authors: Greg Trottier; Monique J Roobol; Nathan Lawrentschuk; Peter J Boström; Kimberly A Fernandes; Antonio Finelli; Karen Chadwick; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Alexandre R Zlotta; Neil E Fleshner
Journal: BJU Int Date: 2011-04-20 Impact factor: 5.588

Prostate-specific antigen screening can be beneficial to younger and at-risk men.

1. Comorbidity and mortality results from a randomized prostate cancer screening trial.

2. Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions.

3. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

4. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.

5. Prostate-cancer mortality at 11 years of follow-up.

6. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

7. PSA screening among elderly men with limited life expectancies.

8. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.

Review 9. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.

10. Randomised prostate cancer screening trial: 20 year follow-up.

1. Data to support PSA screening for younger men lacking.

2. Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening.